• 1
    Paul LC. Immunosuppressive drug-induced toxicities compromising the half-life of renal allografts. Transplant Proc 1998; 30: 7S13S.
  • 2
    Bennett WM, Demattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy. Kidney Int 1996; 50: 10891100.
  • 3
    Bennett WM, Burdmann EA, Andoh TF, Houghton DC, Lindsley J, Elzinga LW. Nephrotoxicity of immunosuppressive drugs. Nephrol Dial Transplant 1994; 9: 141145.
  • 4
    Andoh TF, Burdmann EA, Fransechini N, Hougton DC, Bennett WM. Comparison of acute rapamycine nephrotoxicity with cyclosporine and FK506. Kidney Int 1996; 50: 11101117.
  • 5
    Remuzzi G, Perico N. Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int 1995; 48: S70S74.
  • 6
    Pankewycz OG, Miao L, Isaacs R et al. Increased renal tubular expression of transforming growth factor beta in human allografts correlates with cyclosporine toxicity. Kidney Int 1996; 50: 16341640.
  • 7
    Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM. Rapamycin. A novel immunosuppressive macrolide. Med Res Rev 1994; 14: 122.
  • 8
    Morris RE. Rapamycin: antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev 1992; 6: 3987.
  • 9
    Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibit cell cycle regulators of proliferation in vascular smooth muscle cell. Circ Res 1995; 76: 412417.
  • 10
    Pham SM, Shears LL, Kawaharadan S, Li S, Venkataramanan R, Sehgal S. High local production of nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis. Transplant Proc 1998; 30: 953954.
  • 11
    Dijoseph JF, Mihatsch MJ, Sehgal SN. Renal effects of rapamycin in the spontaneously hypertensive rat. Transplant Int 1994; 7: 8388.
  • 12
    Golbaekdal K, Nielsen CB, Djuhuus JC, Pedersen EB. Effects of rapamycin on renal hemodynamics water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressin in pigs. Transplantation 1994; 58: 11531157.
  • 13
    Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 209216.
  • 14
    Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche H-U, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 10401046.
  • 15
    Kahan BD for The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194202.
  • 16
    MacDonald AS for The Rapamune Global Study Group. A worldwide, phase III, randomised, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2000; 71: 271280.
  • 17
    Groth CG, Bäckman L, Morales JM et al. Sirolimus (Rapamycin)-based therapy in human renal transplantation. similar efficacy and different toxicity compared with cyclosporin. Transplantation 1999; 67: 10361042.
  • 18
    Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 12521260.
  • 19
    Holt DW, Johnson A. Delivering quality for measurement of immunosuppressive drugs: current performance and future needs. Accreditation Quality Assurance 1999; 4: 427430.
  • 20
    Nankivell BD, Gruenwald SM, Allen RDM, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 16831689.
  • 21
    Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths C. Efficacy of sirolimus (Rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporine in the treatment of severe psoriasis. Br J Dermatol 2001; 145: 438445.
  • 22
    Flechner S, Modlin CS, Serrano DP et al. Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplantation 1996; 62: 12351241.
  • 23
    Johnson CP, McBride M, Cherikh WS et al. Renal function in the first year after transplantation predicts longterm survival. Am J Transplantation 2001; 1 (Suppl. 1): 146.
  • 24
    Al Khursany I, Thomas TH, Harrison K, Wilkinson R. Reduced erythrocyte and leukocyte magnesium is associated with cyclosporin treatment and hypertension in renal transplant patients. Nephrol Dial Transplant 1992; 7: 251255.
  • 25
    Nozue T, Kobayashi A, Kodama T et al. Pathogenesis of cyclosporine-induced hypomagnesemia. J Pediatr 1992; 120: 638640.
  • 26
    Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000; 283: 633638.
  • 27
    Flechner SM, Goldfarb DA, Modlin C et al. A prospective randomized trial of sirolimus vs. cyclosporine in kidney transplantation: impact of calcineurin inhibitor elimination on renal function. Am J Transplantation 2001; 1 (Suppl. 1): 172.
  • 28
    Johnson RWG, Kreis H, Oberbauer R et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777786.